INMB
Price:
$4.9
Market Cap:
$108.65M
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsb...[Read more]
Industry
Biotechnology
IPO Date
2019-02-04
Stock Exchange
NASDAQ
Ticker
INMB
According to INmune Bio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 78.01M. This represents a change of -46.33% compared to the average of 145.35M of the last 4 quarters.
The mean historical Enterprise Value of INmune Bio, Inc. over the last ten years is 105.94M. The current 78.01M Enterprise Value has changed 7.26% with respect to the historical average. Over the past ten years (40 quarters), INMB's Enterprise Value was at its highest in in the September 2021 quarter at 266.60M. The Enterprise Value was at its lowest in in the September 2016 quarter at 0.
Average
105.94M
Median
89.63M
Minimum
52.75M
Maximum
184.64M
Discovering the peaks and valleys of INmune Bio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 249.99%
Maximum Annual Enterprise Value = 184.64M
Minimum Annual Increase = -43.16%
Minimum Annual Enterprise Value = 52.75M
Year | Enterprise Value | Change |
---|---|---|
2023 | 177.05M | 130.49% |
2022 | 76.82M | -26.81% |
2021 | 104.96M | -43.16% |
2020 | 184.64M | 249.99% |
2019 | 52.75M | -41.03% |
2018 | 89.46M | 1.34% |
2017 | 88.27M | -1.76% |
2016 | 89.85M | 0.25% |
The current Enterprise Value of INmune Bio, Inc. (INMB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
119.61M
5-year avg
119.24M
10-year avg
105.94M
INmune Bio, Inc.’s Enterprise Value is greater than TFF Pharmaceuticals, Inc. (-1266506.00), greater than Anebulo Pharmaceuticals, Inc. (36.07M), less than Abcam plc (134.60M), greater than AN2 Therapeutics, Inc. (9.52M), greater than Cue Biopharma, Inc. (46.78M), less than Anixa Biosciences, Inc. (101.34M), greater than IN8bio, Inc. (23.87M), greater than PolyPid Ltd. (25.76M), greater than Aerovate Therapeutics, Inc. (46.52M), less than Eliem Therapeutics, Inc. (0), less than Decibel Therapeutics, Inc. (102.82M), less than Anavex Life Sciences Corp. (551.48M), greater than Cassava Sciences, Inc. (5.94M), greater than BioVie Inc. (37.00M), greater than Cognition Therapeutics, Inc. (-3818804.00), less than TScan Therapeutics, Inc. (196.87M), greater than Dermata Therapeutics, Inc. (-3205046.00),
Company | Enterprise Value | Market cap |
---|---|---|
-1266506.00 | $1.29M | |
36.07M | $37.47M | |
134.60M | $5.52B | |
9.52M | $43.03M | |
46.78M | $69.69M | |
101.34M | $102.33M | |
23.87M | $22.40M | |
25.76M | $20.55M | |
46.52M | $77.09M | |
0 | $342.68M | |
102.82M | $123.37M | |
551.48M | $690.24M | |
5.94M | $154.92M | |
37.00M | $53.30M | |
-3818804.00 | $17.61M | |
196.87M | $239.63M | |
-3205046.00 | $2.94M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like INmune Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like INmune Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is INmune Bio, Inc.'s Enterprise Value?
What is the highest Enterprise Value for INmune Bio, Inc. (INMB)?
What is the 3-year average Enterprise Value for INmune Bio, Inc. (INMB)?
What is the 5-year average Enterprise Value for INmune Bio, Inc. (INMB)?
How does the current Enterprise Value for INmune Bio, Inc. (INMB) compare to its historical average?